Aspira Women's Health Inc. (AWHL) vs ProPhase Labs, Inc. (PRPH)

Aspira Women's Health Inc. and ProPhase Labs, Inc. are both Diagnostics & Research companies. Aspira Women's Health Inc. is the larger, with a market value of $2.4M against $1.2M — 2.1× the size. Aspira Women's Health Inc. grew revenue faster over the last twelve months: −8.00% against −43.5%. Aspira Women's Health Inc. has the higher net margin (−117.1% vs −717.4%) and the higher return on invested capital (0.00% vs −387.3%). Across the 17 metrics below, Aspira Women's Health Inc. leads on 12 and ProPhase Labs, Inc. on 5.

Valuation

Metric AWHL PRPH Diagnostics & Research median
P/E n/m n/m 34.52
P/S 0.98 0.04 4.24
P/B n/m n/m 3.42
Price to free cash flow n/m n/m 33.51
EV/EBITDA n/m n/m 23.44
EV/Sales 1.16 1.84 5.18
Earnings yield (128.42%) (25,845.00%) (1.50%)
Free cash flow yield (56.24%) (3,945.49%) 0.00%

Profitability

Metric AWHL PRPH Diagnostics & Research median
Gross margin 58.78% 16.38% 48.32%
Operating margin (80.75%) (498.73%) (5.68%)
Net margin (117.07%) (717.43%) (4.10%)
Free cash flow margin (55.32%) (175.22%) 0.00%
Return on equity 201.29% (543.95%) 0.00%
Return on assets (213.58%) (45.53%) (6.05%)
Return on invested capital 0.00% (387.30%) 0.00%

Growth

Metric AWHL PRPH Diagnostics & Research median
Revenue growth (TTM) (8.00%) (43.52%) 8.99%
EPS growth (last fiscal year) 60.22% 93.33% 20.36%
Revenue growth, 5-year CAGR 14.66% (21.43%) 7.30%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AWHL PRPH Diagnostics & Research median
Debt to equity (0.27) (1.82) 0.01
Current ratio 0.52 0.05 2.27
Net debt to EBITDA 0.00 (0.74) 0.68

Dividend

Metric AWHL PRPH Diagnostics & Research median
Dividend yield — — 0.67%
Payout ratio — — 0.20

Size

Metric AWHL PRPH Diagnostics & Research median
Market cap 2.44m 1.17m 2.22b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack